Lost Ground: Cancer Screening in the COVID-19 Era
A pandemic-related drop in cancer diagnoses could spell long-term trouble for patients and providers.
A pandemic-related drop in cancer diagnoses could spell long-term trouble for patients and providers.
From - Diagnostic Testing & Emerging Technologies
Precision medicine and biomarkers can help the U.S. Food and Drug Administration (FDA) ensure safety of…
From - Diagnostic Testing & Emerging Technologies
Increasing diagnostic options for providers and patients was a common theme throughout panel discussions and presentations at…
From - Diagnostic Testing & Emerging Technologies
Despite appealing the Centers for Medicare and Medicaid's (CMS) sanctions resulting from inspection of…
From - Diagnostic Testing & Emerging Technologies
Experts say the next big advance in achieving a healthier weight will be to use an individual's genetic data to customize diets and…
From - Diagnostic Testing & Emerging Technologies
Clinical whole-exome sequencing (WES) has been utilized for both pediatric and adult patients with…
From - Diagnostic Testing & Emerging Technologies
As use of clinical molecular testing skyrockets, many believe a closer examination of ordering patterns is warranted. Molecular tests have the potential to…